PacBio

PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

14 January 2025 – Menlo Park, California US – PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics. The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic...

PacBio Announces the HiFi Solves Sub-fertility Consortium in Asia Pacific

Collaboration Aims to Harness HiFi Sequencing to Improve Diagnosis and Treatment of Subfertility and Recurrent Pregnancy Loss HiFi Solves Sub-fertility Consortium, an innovative collaboration involving five leading centers across the Asia-Pacific region, announces work aimed at redefining the landscape of fertility research. Utilizing PacBio HiFi long-read sequencing, the consortium, led by KK Women’s and Children’s...

Novogene to Power Cancer, Rare Disease, and Environmental Research with PacBio Sequencing

Highly accurate long-read sequencing data will be used at Novogene’s new lab in Munich, supporting customers across a network of leading research institutions July 23, 2024, California, US –PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that Novogene is using its Revio long-read sequencing system to expand the capabilities...

The Race For Answers: How Radboud University Medical Center Is Reducing The Time It Takes To Identify Rare Diseases

26 February 2024 – Nijmegen, the Netherlands – According to the United States’ National Institute of Health, an estimated 7,000 rare diseases collectively impact between 3.5% to 5.9% of the global population. In the EU alone, this equates to 36 million people. One of the most challenging aspects of rare diseases is being able to identify...

PacBio Announces Onso, the Highly Accurate Short-Read Sequencing Platform

MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ ó PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of external beta testing of the Onso™ Sequencing System. This innovative benchtop short-read DNA sequencing platform is expected to provide an extraordinary level of accuracy by utilizing PacBioís unique sequencing by...

PacBio Announces a New Informatics Analysis Method for Highly Homologous Genes

MENLO PARK, Calif., March 14, 2022 /PRNewswire/ - PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a new informatics method that genotypes gene paralogs and pseudogenes with high accuracy. The new computational tool, named 'Paraphase,' enables variant calling, copy number analysis and phasing by identifying the full gene sequence of...
1305 O’Brien Drive Menlo Park, CA 94025